DE3400491C2 - - Google Patents
Info
- Publication number
- DE3400491C2 DE3400491C2 DE3400491A DE3400491A DE3400491C2 DE 3400491 C2 DE3400491 C2 DE 3400491C2 DE 3400491 A DE3400491 A DE 3400491A DE 3400491 A DE3400491 A DE 3400491A DE 3400491 C2 DE3400491 C2 DE 3400491C2
- Authority
- DE
- Germany
- Prior art keywords
- resinate
- formula
- resin
- acid
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000011347 resin Substances 0.000 claims description 24
- 229920005989 resin Polymers 0.000 claims description 24
- 239000004480 active ingredient Substances 0.000 claims description 19
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 229920001268 Cholestyramine Polymers 0.000 claims description 7
- KNDHRUPPBXRELB-UHFFFAOYSA-M [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride Chemical group [Cl-].C1=CC(CC)=CC=C1C(C)CCC1=CC=C([N+](C)(C)C)C=C1 KNDHRUPPBXRELB-UHFFFAOYSA-M 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 229960001678 colestyramine Drugs 0.000 claims description 7
- 229920001577 copolymer Polymers 0.000 claims description 6
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 5
- 150000001450 anions Chemical class 0.000 claims description 4
- 238000011068 loading method Methods 0.000 claims description 3
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 2
- 238000009736 wetting Methods 0.000 claims 2
- 238000005342 ion exchange Methods 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000002775 capsule Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 229920002472 Starch Polymers 0.000 description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000002585 base Substances 0.000 description 5
- 159000000000 sodium salts Chemical class 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 229960001193 diclofenac sodium Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 229940014259 gelatin Drugs 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- -1 2,6-dichloroanilino Chemical group 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical group C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 229940100445 wheat starch Drugs 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000008098 Oxalis acetosella Nutrition 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000126309 Trifolium dubium Species 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- MPMBRWOOISTHJV-UHFFFAOYSA-N but-1-enylbenzene Chemical compound CCC=CC1=CC=CC=C1 MPMBRWOOISTHJV-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000008183 oral pharmaceutical preparation Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F8/00—Chemical modification by after-treatment
- C08F8/44—Preparation of metal salts or ammonium salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH14783A CH655507B (en, 2012) | 1983-01-12 | 1983-01-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3400491A1 DE3400491A1 (de) | 1984-07-12 |
| DE3400491C2 true DE3400491C2 (en, 2012) | 1988-11-10 |
Family
ID=4180317
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE8484810008T Expired DE3474152D1 (en) | 1983-01-12 | 1984-01-06 | Substituted carboxylic-acid resins, process for their manafacture, use thereof and pharmaceutical compositions containing these resins |
| DE19843400491 Granted DE3400491A1 (de) | 1983-01-12 | 1984-01-09 | Resinat einer substituierten carbonsaeure, verfahren zu seiner herstellung, seine verwendung und dieses enthaltende pharmazeutische praeparate |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE8484810008T Expired DE3474152D1 (en) | 1983-01-12 | 1984-01-06 | Substituted carboxylic-acid resins, process for their manafacture, use thereof and pharmaceutical compositions containing these resins |
Country Status (41)
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH664085A5 (de) * | 1985-02-08 | 1988-02-15 | Ciba Geigy Ag | Pharmazeutische praeparate mit analgetischer wirksamkeit, sowie deren herstellung. |
| ES8604955A1 (es) * | 1985-11-08 | 1986-03-16 | Covex Sa | Procedimiento para la preparacion de resinatos de la (-) eburnamenina-14-(15h)-ona |
| GB8730010D0 (en) * | 1987-12-23 | 1988-02-03 | Smith Kline French Lab | Compounds |
| US5230885A (en) * | 1987-12-23 | 1993-07-27 | Smith Kline & French Laboratories Limited | Polystyrene anion exchange polymer pharmaceutical composition |
| AU608114B2 (en) * | 1987-12-23 | 1991-03-21 | Smith Kline & French Laboratories Limited | Compounds |
| CH675537A5 (en, 2012) * | 1988-03-25 | 1990-10-15 | Ciba Geigy Ag | |
| SE509029C2 (sv) * | 1988-08-16 | 1998-11-30 | Ss Pharmaceutical Co | Långtidsverkande diklofenak-natriumpreparat |
| US4960799A (en) * | 1988-09-13 | 1990-10-02 | Ciba-Geigy Corporation | Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use |
| ATE87476T1 (de) * | 1988-11-10 | 1993-04-15 | Ciba Geigy Ag | Fluessige orale formulierung. |
| CA2002492A1 (en) * | 1988-11-11 | 1990-05-11 | Sandra T. A. Malkowska | Pharmaceutical ion exchange resin composition |
| GB8911719D0 (en) * | 1989-05-22 | 1989-07-05 | Smith Kline French Lab | Compounds |
| GB8913699D0 (en) * | 1989-06-14 | 1989-08-02 | Smith Kline French Lab | Compounds |
| GB8913700D0 (en) * | 1989-06-14 | 1989-08-02 | Smith Kline French Lab | Compounds |
| US5079001A (en) * | 1989-11-03 | 1992-01-07 | Ciba-Geigy Corporation | Liquid oral formulation of diclofenac |
| GB8928278D0 (en) * | 1989-12-14 | 1990-02-21 | Smith Kline French Lab | Compounds |
| SE9004129D0 (sv) * | 1990-12-21 | 1990-12-21 | Pharmacia Lkb Biotech | Anion exchanger |
| AU2259692A (en) * | 1991-07-03 | 1993-02-11 | Sano Corporation | Composition and method for transdermal delivery of diclofenac |
| US20020176842A1 (en) * | 2001-04-09 | 2002-11-28 | Lyn Hughes | Extended release of active ingredients |
| EP1250937B1 (en) * | 2001-04-09 | 2009-05-13 | Rohm And Haas Company | Controlled dissolution of active ingredients |
| US20030180249A1 (en) * | 2002-03-18 | 2003-09-25 | Khanna Satish Chandra | Dosage forms for hygroscopic active ingredients |
| RU2221559C1 (ru) * | 2002-11-15 | 2004-01-20 | Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" | Препарат диклофенак натрия длительного действия |
| US20050036977A1 (en) * | 2003-08-11 | 2005-02-17 | Dilip Gole | Taste-masked resinate and preparation thereof |
| EP1830851A2 (en) * | 2004-12-06 | 2007-09-12 | Themis Laboratories Private Limited | Rapid disintegrating taste masked compositions and a process for its preparations |
| BRPI0709606B8 (pt) | 2006-03-16 | 2021-05-25 | Tris Pharma Inc | suspensão líquida administrável oralmente com características de liberação modificada |
| US7799347B2 (en) * | 2006-09-07 | 2010-09-21 | Chondrex Inc. | Endotoxin-adsorbent for the prevention and treatment of autoimmune diseases |
| US8647666B2 (en) * | 2008-10-02 | 2014-02-11 | University of Pittsburgh—of the Commonwealth System of Higher Education | Administration of an adsorbent polymer for treatment of systemic inflammation |
| MX377251B (es) | 2010-03-24 | 2025-03-07 | Jazz Pharmaceuticals Inc Star | Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas. |
| BR112015003120B1 (pt) | 2012-08-15 | 2022-08-09 | Tris Pharma , Inc | Tablete mastigável de liberação estendida de metilfenidato e seu uso |
| US10398662B1 (en) | 2015-02-18 | 2019-09-03 | Jazz Pharma Ireland Limited | GHB formulation and method for its manufacture |
| US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US20180263936A1 (en) | 2017-03-17 | 2018-09-20 | Jazz Pharmaceuticals Ireland Limited | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
| US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
| US11400052B2 (en) | 2018-11-19 | 2022-08-02 | Jazz Pharmaceuticals Ireland Limited | Alcohol-resistant drug formulations |
| WO2020178695A1 (en) | 2019-03-01 | 2020-09-10 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| TW202139986A (zh) | 2020-02-21 | 2021-11-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | 治療原發性嗜睡症之方法 |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB857193A (en) * | 1957-03-14 | 1960-12-29 | Clinical Products Ltd | Resin-drug compounds |
| GB823000A (en) * | 1957-10-03 | 1959-11-04 | Clinical Products Ltd | Resin-drug compounds |
| GB869149A (en) * | 1958-09-16 | 1961-05-31 | Clinical Products Ltd | Liquid pharmaceutical compositions comprising compounds of ion exchange resins and therapeutic substances |
| US3316282A (en) * | 1965-02-08 | 1967-04-25 | Squibb & Sons Inc | Anion exchange resin complex of a cycloborate ester of a steroid |
| NL6817965A (en, 2012) * | 1967-12-20 | 1969-06-24 | ||
| CH519476A (de) * | 1968-03-30 | 1972-02-29 | Hoechst Ag | Verfahren zur Herstellung von Salzen von Acylamino-alkylbenzolsulfonyl-harnstoffen mit Anionenaustauschern |
| US3926864A (en) * | 1971-06-21 | 1975-12-16 | Ionics | Ion exchange membranes having a macroporous surface area |
| GB1423694A (en) * | 1973-07-10 | 1976-02-04 | Beecham Group Ltd | Pharmaceutical compositions |
| US4058491A (en) * | 1975-02-11 | 1977-11-15 | Plastomedical Sciences, Inc. | Cationic hydrogels based on heterocyclic N-vinyl monomers |
| FR2352547A1 (fr) * | 1976-05-25 | 1977-12-23 | Viridis Ets | Nouvelle resine anionique a action hypocholesterolemiante, son procede de preparation et compositions therapeutiques la contenant |
| US4217421A (en) * | 1977-06-27 | 1980-08-12 | Rohm And Haas Company | Anion exchange resins prepared from crosslinked polystyrenesulfonylchloride |
| US4380590A (en) * | 1978-09-19 | 1983-04-19 | Rohm And Haas Company | Emulsion copolymer cation exchange resins |
| IT1106718B (it) * | 1978-12-21 | 1985-11-18 | Alfa Farmaceutici Spa | Composizioni a base di resine anioniche salificate farmacologicamente attive |
| US4207399A (en) * | 1979-03-14 | 1980-06-10 | Rohm And Haas Company | Methylquinoline high polymer based on quaternary ammonium polymers |
| US4302548A (en) * | 1980-05-22 | 1981-11-24 | Rohm And Haas Company | Production of ion exchange resins, the resins so produced and ion exchange processes using them |
-
1983
- 1983-01-12 CH CH14783A patent/CH655507B/de not_active IP Right Cessation
-
1984
- 1984-01-02 AT AT0000784A patent/AT391467B/de not_active IP Right Cessation
- 1984-01-05 MT MT943A patent/MTP943B/xx unknown
- 1984-01-06 MA MA20221A patent/MA20000A1/fr unknown
- 1984-01-06 US US06/568,976 patent/US4510128A/en not_active Expired - Lifetime
- 1984-01-06 EP EP84810008A patent/EP0122219B1/de not_active Expired
- 1984-01-06 GB GB08400251A patent/GB2134529B/en not_active Expired
- 1984-01-06 AT AT84810008T patent/ATE37378T1/de not_active IP Right Cessation
- 1984-01-06 DE DE8484810008T patent/DE3474152D1/de not_active Expired
- 1984-01-09 RO RO84113260A patent/RO88481A/ro unknown
- 1984-01-09 FI FI840069A patent/FI82682C/fi not_active IP Right Cessation
- 1984-01-09 CS CS84178A patent/CS269954B2/cs unknown
- 1984-01-09 PT PT77932A patent/PT77932B/pt unknown
- 1984-01-09 DE DE19843400491 patent/DE3400491A1/de active Granted
- 1984-01-10 ES ES528770A patent/ES8504849A1/es not_active Expired
- 1984-01-10 FR FR8400288A patent/FR2542735B1/fr not_active Expired
- 1984-01-10 ZW ZW4/84A patent/ZW484A1/xx unknown
- 1984-01-10 CA CA000445018A patent/CA1218077A/en not_active Expired
- 1984-01-10 GR GR73478A patent/GR79793B/el unknown
- 1984-01-10 IT IT47527/84A patent/IT1177501B/it active
- 1984-01-10 SE SE8400098A patent/SE457959B/sv not_active IP Right Cessation
- 1984-01-10 PL PL1984245656A patent/PL142737B1/pl unknown
- 1984-01-10 AR AR295384A patent/AR240310A1/es active
- 1984-01-10 DZ DZ847047A patent/DZ593A1/fr active
- 1984-01-10 DD DD84259312A patent/DD218373A5/de not_active IP Right Cessation
- 1984-01-10 OA OA58200A patent/OA07628A/xx unknown
- 1984-01-10 MC MC841684A patent/MC1564A1/xx unknown
- 1984-01-11 PH PH30094A patent/PH21795A/en unknown
- 1984-01-11 IE IE49/84A patent/IE56545B1/en not_active IP Right Cessation
- 1984-01-11 KR KR1019840000085A patent/KR900006747B1/ko not_active Expired
- 1984-01-11 NZ NZ206815A patent/NZ206815A/en unknown
- 1984-01-11 DK DK011884A patent/DK166683B1/da not_active IP Right Cessation
- 1984-01-11 IL IL70660A patent/IL70660A/xx not_active IP Right Cessation
- 1984-01-11 NO NO840090A patent/NO162862C/no not_active IP Right Cessation
- 1984-01-11 LU LU85171A patent/LU85171A1/de unknown
- 1984-01-11 AU AU23230/84A patent/AU570230B2/en not_active Expired
- 1984-01-11 HU HU8473A patent/HU190750B/hu unknown
- 1984-01-11 BE BE0/212185A patent/BE898649A/fr not_active IP Right Cessation
- 1984-01-11 JP JP59002106A patent/JPS59134759A/ja active Granted
- 1984-01-11 ZA ZA84212A patent/ZA84212B/xx unknown
- 1984-01-11 NL NL8400098A patent/NL8400098A/nl not_active Application Discontinuation
- 1984-01-14 EG EG26/84A patent/EG16562A/xx active
-
1990
- 1990-11-01 HK HK903/90A patent/HK90390A/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3400491C2 (en, 2012) | ||
| DE3852781T2 (de) | Präparat mit verzögerter Freisetzung sowie dessen Herstellung. | |
| DE68912882T2 (de) | Wirkstoff-Harzkomplexe mit verzögerter Freigabe. | |
| DE69100991T2 (de) | Pharmazeutische formulierungen. | |
| DE69002604T2 (de) | Pharmazeutische Zubereitung mit verzögerter Freisetzung und seine Herstellung. | |
| DE69619250T2 (de) | Verbesserte arzneimittel mit einem ionenaustauschharz | |
| DE68909023T2 (de) | Verzögerte Multipartikel-Zusammensetzung für orale Anwendung. | |
| DE69115711T2 (de) | Verfahren zur arzneiformulierung sowie arzneimittel | |
| DE69208299T2 (de) | Feste Arzneizubereitungen zur oralen Verabreichung mit verlängerter Magenverweilzeit | |
| DE69105106T2 (de) | Im wasser schnell suspendierbare pharmazeutische zusammensetzung. | |
| DE69105222T2 (de) | Auf quervernetzte Polymere aufgebrachte und mit Polymerfilmen beschichtete therapeutische Zusammensetzungen mit kontrollierter Freisetzung von Medikamenten und deren Herstellungsverfahren. | |
| DE69423028T2 (de) | Zubereitung mit kontrollierter freisetzung, die ein morphinsalz enthält | |
| DE3783163T2 (de) | Arzneimittelzubereitungen mit verzoegerter freisetzung. | |
| DE60108255T2 (de) | Clarithromycin enthaltende zubereitung mit verlängerter freisetzung | |
| DE3438291A1 (de) | Verfahren zur herstellung einer waessrigen ueberzugsmitteldispersion und ihre verwendung zum ueberziehen von arzneimitteln | |
| DE2246037A1 (de) | Peroral anwendbares arzneimittel mit verstaerkter resorptionsverzoegerung | |
| CH640727A5 (en) | Tablet or other solid, compressed article | |
| DE1258548B (de) | Verfahren zur Herstellung von Arzneimitteltabletten unter Verwendung von Kunstharzen als die Wirkstoffabgabe verzoegernde Einbettungsmassen | |
| DE10254412A1 (de) | Arzneimittel | |
| DE60133028T2 (de) | Mikrogranulat auf wirkstoffbasis und verfahren zu seiner herstellung | |
| DE60005012T2 (de) | Geschmacksmaskierte zubereitungen | |
| CH639869A5 (en) | Process for preparing a biologically active gel | |
| DE69309377T2 (de) | Mikronährstoff-Zusammensetzungen | |
| DE3036449C2 (de) | Verfahren zur Herstellung einer eine physiologisch aktive Substanz enthaltenden Zusammensetzung mit kontrollierter Wirkstoffreigabe | |
| WO1993010766A1 (de) | Ein flurbiprofen enthaltendes akutarzneimittel und seine verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| 8125 | Change of the main classification |
Ipc: C08F 8/30 |
|
| D2 | Grant after examination | ||
| 8380 | Miscellaneous part iii |
Free format text: SEITE 2, ZEILE 35 "CH" AENDERN IN "CH(PFEIL ABWAERTS)2(PFEIL ABWAERTS) |
|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |